ERBB2 and breast carcinoma: Consequently, the randomized, multicenter, double-blind, placebo-controlled phase III PEONY trial (NCT02586025) was conducted to compare the efficacy, safety, and tolerability of adding pertuzumab to trastuzumab and docetaxel in Asian patients with HER2-positive early or locally advanced breast cancer.